AZN: H1 2019 Results
AstraZeneca PLC 25 July 2019 07:00 BST H1 2019 Results Continuing strong top-line performance underpins confidence in sustainable growth First-half Product Sales growth of 12% (17% at CER1) to $11,183m included an acceleration in second-quarter Product Sales to $5,718m (+14%, +19% at CER). The second quarter saw every sales region and all three therapy areas deliver an encouraging performance, including: - The sustained performance of new medicines2 (+66%, +72% at CER) to $2,385m - Sales growth by therapy area in the quarter: Oncology +51% (+57%